Home

This technology enables rapid, non-invasive detection and differentiation of all four dengue virus serotypes using saliva samples, with advanced qPCR and RT-LAMP assays, making dengue diagnosis easier, faster, and more accessible without the need for blood draws. Background:
Dengue virus (DENV) is a major global health concern, with hundreds of millions of infections occurring annually, particularly in tropical and subtropical regions. Accurate and timely diagnosis is crucial for effective patient management and for controlling outbreaks, especially since infection with one DENV serotype can increase the risk of severe disease upon subsequent infection with a different serotype. Traditionally, DENV diagnostics have relied on blood-based methods, which require trained phlebotomists, specialized equipment, and can be invasive and uncomfortable for patients. This reliance on blood samples poses significant challenges in resource-limited settings, where access to healthcare infrastructure and skilled personnel may be limited, and where rapid, large-scale testing is often needed during outbreaks. Current diagnostic approaches for DENV, such as conventional PCR and serological tests, face several limitations. Blood-based PCR assays, while sensitive, often require complex sample preparation, including RNA purification, and are susceptible to inhibitors present in crude samples, which can compromise accuracy. Serological assays, on the other hand, may not reliably distinguish between DENV serotypes or between primary and secondary infections, leading to potential misdiagnosis. Furthermore, the need for cold chain storage, specialized reagents, and laboratory infrastructure restricts the deployment of these tests in field or point-of-care settings. These challenges highlight the need for more accessible, rapid, and non-invasive diagnostic solutions that can be implemented widely, particularly in outbreak-prone and resource-constrained environments.Technology Overview:  
This technology provides a rapid, non-invasive diagnostic solution for detecting and differentiating all four dengue virus (DENV) serotypes using saliva samples. It integrates two advanced nucleic acid testing methods: a multiplex quantitative PCR (qPCR) assay and a reverse transcription loop-mediated isothermal amplification (RT-LAMP) assay. The multiplex qPCR can simultaneously identify DENV1–4 and a human internal control in under 90 minutes, with high sensitivity down to 3–5 viral RNA copies per microliter, and is compatible with both purified and crude saliva samples. The RT-LAMP assay, operating at a single temperature, delivers serotype-specific results in as little as 7–15 minutes and supports simple colorimetric or lateral-flow readouts, making it suitable for point-of-care settings. Both methods use standard commercial reagents and are designed for ease of use, eliminating the need for trained phlebotomists and enabling deployment in resource-limited environments. This technology is differentiated by its comprehensive approach to dengue diagnostics, leveraging large-scale genomic analysis to design highly specific primers and probes that ensure accurate serotype identification directly from saliva. Unlike traditional blood-based tests, this solution offers a non-invasive alternative that is easier to administer and more acceptable to patients, particularly in mass screening or pediatric contexts. The assays have been validated through rigorous human challenge studies and transcriptomic analyses, demonstrating comparable sensitivity and specificity to blood-based methods while also providing insights into host immune responses. Its compatibility with digital PCR and whole-genome sequencing further enhances its utility for research and epidemiological surveillance. The combination of rapid turnaround, high accuracy, non-invasive sampling, and adaptability to point-of-care use positions this technology as a significant advancement in global dengue management and public health diagnostics. https://suny.technologypublisher.com/files/sites/adobestock_349162542.jpegAdvantages:  
•    Non-invasive detection of all four Dengue virus serotypes using saliva samples, eliminating the need for blood draws.
•    Rapid results with multiplex qPCR providing detection in under 90 minutes and RT-LAMP assays delivering results within 7–15 minutes.
•    High sensitivity and specificity by targeting conserved, serotype-distinct genomic regions, with detection limits as low as ~3 copies/µL.
•    Compatibility with point-of-care settings due to tolerance of crude saliva inhibitors and use of standard commercial enzymes and reagents.
•    Supports multiple readout formats including fluorescent, colorimetric, and lateral-flow assays for flexible diagnostic use.
•    Enables viral RNA quantification and whole-genome sequencing directly from saliva, facilitating detailed viral analysis and surveillance.
•    Reduces reliance on trained medical personnel and specialized equipment, improving accessibility in resource-limited environments.
•    Potential to enhance understanding of host immune responses through saliva transcriptomic analysis alongside viral detection. Applications:  
•    Point-of-care dengue screening
•    Rapid outbreak surveillance
•    At-home dengue self-testing
•    Clinical trial participant monitoring
•    Travel health screening Intellectual Property Summary:
Patent application filed: 63/924,381, filed on 11/24/2025
Know-how basedStage of Development:
Design of highly specific primers and probes in hand, that ensure accurate serotype identification directly from saliva. TRL level 4.Licensing Status:
This technology is available for licensing.
 

This technology is a single-chain IgA1 antibody delivered by DNA or RNA, enabling the body to produce its own dengue-neutralizing antibodies safely and quickly, without the risk of worsening infection, for rapid prevention and treatment of flavivirus diseases. Background:
The field of flavivirus therapeutics, particularly for diseases like dengue, is of critical global importance due to the widespread prevalence and significant morbidity and mortality associated with these infections. Dengue alone threatens nearly 40% of the world’s population, causing hundreds of millions of infections each year. Despite this immense burden, effective prevention and treatment options remain limited. The absence of broadly effective vaccines, especially for individuals without prior exposure, and the lack of approved monoclonal antibody therapies highlight a pressing need for innovative solutions. Rapid, scalable, and easily deployable interventions are especially crucial during outbreaks, when traditional manufacturing and distribution methods for biologics can be too slow or resource-intensive to meet urgent demand. Current approaches to monoclonal antibody therapy for flaviviruses face several significant challenges. Conventional antibodies are complex molecules composed of separate heavy and light chains, requiring intricate and costly manufacturing processes, as well as specialized equipment for administration, such as intravenous infusions. These logistical hurdles hinder timely deployment, particularly in resource-limited settings or during sudden outbreaks. Furthermore, the predominant use of the IgG isotype in antibody therapies introduces a major safety concern: Antibody Dependent Enhancement (ADE), where antibodies can paradoxically worsen infection in partially immune individuals. This phenomenon has stymied the development of safe and effective antibody-based interventions for dengue, as IgG antibodies can facilitate viral entry into host cells and exacerbate disease severity. As a result, there is a critical unmet need for antibody-based therapies that are both safe from ADE and compatible with rapid, cost-effective, and scalable delivery platforms.Technology Overview:  
This technology is a single-chain recombinant IgA1 monoclonal antibody specifically engineered for the treatment and prevention of flavivirus infections, with a primary focus on dengue virus. The construct is designed as a single polypeptide that fuses the heavy and light chain variable regions via a GS3 linker, and incorporates an optimized leader sequence for efficient secretion, a human IgG1 hinge region for flexibility, and the Ca2 and Ca3 domains of the human IgA1 Fc region. This configuration enables the antibody to be delivered through nucleic acid vectors, such as DNA or RNA, allowing the patient’s own cells to produce the therapeutic antibody in vivo. The IgA1 isotype is chosen for its ability to neutralize all four dengue virus serotypes while avoiding Antibody Dependent Enhancement (ADE), a significant safety concern associated with IgG antibodies in dengue therapy. What differentiates this technology is its innovative single-chain design, which overcomes the complexity and inefficiency of delivering separate heavy and light chain genes typically required for monoclonal antibody therapies. By utilizing the IgA1 isotype and a streamlined genetic construct, the solution not only mitigates the risk of ADE but also enables rapid, scalable, and cost-effective production and deployment through nucleic acid delivery platforms. This approach eliminates the need for traditional antibody manufacturing and infusion infrastructure, making it especially valuable for rapid response during outbreaks and in resource-limited settings. Its specific applicability to expecting mothers addresses a unique and vulnerable population. https://suny.technologypublisher.com/files/sites/adobestock_518283890.jpeg Advantages:  
•    Enables in vivo production of therapeutic antibodies via nucleic acid delivery, reducing manufacturing complexity and cost.
•    Neutralizes all four dengue virus serotypes effectively, providing broad protection.
•    IgA1 isotype avoids Antibody Dependent Enhancement (ADE), enhancing safety compared to IgG antibodies.
•    Single-chain design fuses heavy and light chain variable regions, simplifying gene delivery and expression.
•    Rapid and scalable deployment potential for outbreak response without need for specialized infusion equipment.
•    Versatile applications including prophylaxis for travelers, military personnel, endemic populations, and outbreak containment.
•    Optimized molecular design ensures efficient secretion, flexibility, and preserved antibody effector functions. Applications:  
•    Prophylactic treatment for travelers
•    Outbreak containment in endemic regions
•    Rapid deployment for military personnel
•    Immediate post-exposure prophylaxis Intellectual Property Summary:
Know-how basedStage of Development:
TRL 2Licensing Status:
This technology is available for licensing.
 

This technology uses a single-chain IgA1 antibody delivered by DNA or RNA to enable the body to produce its own protection against dengue and Zika viruses, offering rapid, safe, and scalable prevention and treatment without risk of antibody-dependent enhancement. Background:
Flavivirus infections, including those caused by dengue and Zika viruses, represent a significant global health concern, affecting billions of people and resulting in hundreds of millions of infections annually. These diseases can lead to severe illness and death, particularly in regions where healthcare resources are limited and outbreaks are frequent. The lack of effective vaccines or therapeutics for many at-risk populations underscores the urgent need for new approaches to both prevent and treat these infections. Monoclonal antibody therapies have shown promise in neutralizing viral pathogens and providing immediate immunity, making them attractive candidates for outbreak response and prophylactic use in vulnerable populations. However, current monoclonal antibody therapies face several critical limitations that hinder their widespread deployment during flavivirus outbreaks. Traditional antibodies are complex molecules composed of two heavy and two light chains, requiring intricate and costly manufacturing processes in specialized facilities. These therapies are typically administered via intravenous infusion, necessitating trained personnel and advanced medical infrastructure, which are often unavailable in outbreak settings or resource-limited regions. Additionally, IgG-based antibodies carry the risk of Antibody Dependent Enhancement (ADE), a phenomenon that can worsen disease severity in individuals with partial immunity, further complicating their use for dengue and related viruses. Existing nucleic acid-based delivery systems are also challenged by the need to co-express multiple antibody chains, reducing efficiency and scalability for rapid response.Technology Overview:  
This technology is a single-chain recombinant IgA1 monoclonal antibody construct specifically engineered for nucleic acid-based delivery to combat flavivirus infections such as dengue and Zika virus. Unlike conventional monoclonal antibody therapies, which require complex manufacturing and infusion processes, this solution utilizes a single-chain format that fuses the heavy and light chain variable regions into one polypeptide, linked to a truncated IgA1 Fc region. This design allows the antibody to be encoded by a single DNA or RNA molecule, enabling direct in vivo expression after administration. The optimized construct incorporates an engineered leader sequence, a GS3 linker, a human IgG1 hinge, and the Ca2 and Ca3 domains of the human IgA1 Fc, ensuring efficient production and robust neutralizing activity against all four dengue virus serotypes. Importantly, the IgA1 isotype was chosen because it does not mediate Antibody Dependent Enhancement (ADE), a major safety concern in dengue treatment. What differentiates this technology is its novel single-chain IgA1 architecture, which is the first of its kind, as previous single-chain antibody constructs have focused on the IgG1 isotype. The strategic molecular design (combining variable regions, linker, and hinge domains) enables high-level expression and functional activity from a single nucleic acid vector, greatly simplifying manufacturing and deployment. Its compatibility with DNA or RNA delivery platforms means that the antibody can be rapidly and cost-effectively produced and administered, bypassing the need for traditional biomanufacturing and infusion infrastructure. This approach not only addresses the urgent need for safe and effective flavivirus therapeutics but also enables rapid outbreak response, making it suitable for use in travelers, military personnel, residents in endemic regions, and for targeted containment of transmission clusters.https://suny.technologypublisher.com/files/sites/adobestock_56423730.jpegAdvantages:  
•    Enables rapid, scalable, and cost-effective production and delivery of therapeutic antibodies via nucleic acid vectors (DNA/RNA).
•    Single-chain IgA1 antibody format simplifies manufacturing by encoding both heavy and light chain variable regions in a single polypeptide.
•    Provides broad neutralization against all four dengue virus serotypes, addressing a major global health challenge.
•    IgA1 isotype avoids Antibody Dependent Enhancement (ADE), improving safety compared to traditional IgG antibodies.
•    Facilitates immediate immunity for prophylactic and therapeutic use in diverse populations including travelers, military personnel, and residents in endemic areas.
•    Eliminates need for specialized infusion equipment, enabling easier and faster deployment during outbreaks.
•    Preserves unique IgA1 effector functions while optimizing expression and function through engineered molecular design. Applications:  
•    Dengue outbreak rapid response
•    Traveler prophylactic immunization
•    Military deployment disease prevention
•    Close contact post-exposure prophylaxis
•    Endemic region population protection Intellectual Property Summary:
Know-how basedStage of Development:
TRL 3 Licensing Status:
This technology is available for licensing.

This technology employs an engineered self-delivering siRNA to selectively reduce USP10 protein levels in tissues, thereby promoting regenerative healing and suppressing pathological scarring. Preclinical studies in the eye demonstrate a favorable safety profile and robust efficacy, supporting the potential of this approach for treating fibrotic disease across multiple organ systems. Background:
Regenerative healing, particularly in ocular tissues such as the transparent cornea, is a critical area of biomedical research due to the eye’s limited capacity for self-repair and the high risk of vision loss following injury or surgery. Scarring and fibrosis in the cornea can result in permanent visual impairment or blindness, making effective wound healing without scarring a major unmet medical need. Current clinical approaches to treat corneal scarring are limited, with corneal transplantation being the only definitive solution for severe cases. Additionally, in glaucoma surgeries like trabeculectomy, excessive scarring of the surgical site often leads to surgical failure and poor patient outcomes. The need for therapies that can promote regenerative healing while minimizing fibrosis is therefore urgent, not only for ocular health but also for broader applications in tissue repair and organ fibrosis. Existing methods to prevent or treat scarring in the eye, such as the use of antiproliferative agents like mitomycin C, are associated with significant drawbacks, including toxicity, risk of infection, and non-specific inhibition of cell proliferation that can impair normal healing. These treatments do not specifically target the molecular drivers of fibrosis and often result in incomplete or unsatisfactory outcomes. Furthermore, the lack of targeted, non-toxic therapies means that patients frequently require repeated interventions or long-term use of adjunctive medications such as steroids and antibiotics, which carry their own risks and side effects. The limitations of current approaches highlight the need for more precise, effective, and safer therapies that can modulate specific molecular pathways involved in scarring and promote tissue regeneration.Technology Overview:  
This technology comprises a self-delivering small interfering RNA (siRNA) therapeutic designed to selectively suppress ubiquitin-specific peptidase 10 (USP10), thereby shifting wound repair toward regenerative healing and away from fibrosis, with particular relevance to corneal and other ocular tissues. The siRNA duplex is chemically modified for enhanced stability, specificity, and delivery efficiency. The technology has demonstrated potent knockdown of USP10 in cell-based assays, significant acceleration of wound closure, and reduction of fibrosis markers in animal models, as well as enhanced epithelial regeneration in ex vivo human corneas. Safety studies in mice, rabbits, and mini-pigs confirmed the absence of toxicity or adverse ocular effects, supporting its suitability for clinical applications. What differentiates this solution is its combination of a novel therapeutic target (USP10) with a highly optimized, self-delivering siRNA platform that achieves effective gene silencing at lower doses and with minimal dosing frequency. Unlike traditional anti-scarring treatments, which often rely on cytotoxic agents like mitomycin C and carry significant side effects, this approach directly modulates the molecular pathways involved in fibrosis and healing, promoting nerve growth, enabling regenerative repair without the risk of immune or vascular complications. The extensive chemical modifications confer nuclease resistance and improved pharmacokinetics, allowing for topical or parenteral administration without the need for complex delivery vehicles. The platform’s efficacy across multiple preclinical models, broad applicability to various fibrotic conditions, and favorable safety profile position it as a transformative advance in regenerative medicine, potentially reducing the need for invasive procedures like corneal transplantation and offering a new paradigm for treating scarring and fibrosis in both ocular and non-ocular tissues. https://suny.technologypublisher.com/files/sites/adobestock_17056179091.jpegAdvantages:  
•    Promotes regenerative healing and significantly reduces scarring, especially in corneal tissues
•    Self-delivery siRNA technology enables effective USP10 knockdown at low doses without immune or vascular reactions
•    Demonstrated safety and non-toxicity in preclinical animal models with no adverse effects on corneal morphology or function
•    Long-lasting efficacy with effects sustained for at least six weeks post-treatment
•    Potential to improve outcomes in ocular surgeries by preventing fibrosis and scarring that lead to vision loss
•    Versatile delivery options including topical, pulmonary, and parenteral administration with targeted delivery capabilities
•    Broad therapeutic applications beyond ocular healing, including treatment of fibrosis in skin and internal organs
•    Reduces need for adjunctive antibiotic or steroid treatments due to its targeted and effective mechanism Applications:  
•    Corneal wound healing therapy
•    Anti-scarring treatment post-eye surgery
•    Topical therapy for ocular fibrosis
•    Dermal wound regenerative healing
•    Fibrosis treatment in internal organs Intellectual Property Summary:
Patent application PCT/US2025/018729 filed on 3/6/2025 Stage of Development:
TRL5
Supported by data appropriate to its current TRL stage, including compelling efficacy in several preclinical models, broad fibrotic disease applicability, and a strong safety profile, the platform stands poised to drive a major advance in regenerative medicine, offering a less invasive alternative to procedures such as corneal transplantation and a novel pathway for treating fibrosis across tissue types.Licensing Status:
This technology is available for licensing.